Preparing for 2030: Launch Success in Pharma’s Complex Future
In the pharma and biotech industry, those tasked with achieving a successful product launch have always faced challenges, and this is not likely to change any time soon, as we continuously find ourselves grappling with ever-increasing complexity.
By the year 2030, it is clear that launch leaders will need to be capable of strategically navigating an increasingly crowded, dynamic, and competitive market environment.
In this article, we delve into Prescient’s predictions for some of the most pressing issues affecting the future of pharma launches. Expert principals from across our healthcare consultancy team provide their tips for leaders attempting to navigate launches in this period of mounting uncertainty.
Pharma’s 2030 launch horizon
We expect the 2030 pharmaceutical marketing landscape to be shaped predominantly by a series of technological, regulatory, and market-driven transformations. Pharmaceutical companies that can efficiently keep up with these rapid industry changes by incorporating comprehensive and innovative marketing strategies will be much better positioned for success.
Looking toward the 2030 market horizon, launch leaders will need to start placing specific emphasis on harnessing the potential of emerging technology to stay ahead of the competition and accelerate innovation to market. To better position themselves for long-term sustainable growth, they will need to meticulously plan their market access strategies well in advance to prioritize unmet patient needs and deliver value to payers.
Tackling 2030’s pharma launch challenges ‘hands-on’
When addressing the primary launch issues expected to dominate the pharmaceutical industry in 2030, we advise placing particular focus on four key areas.
The following advice aims to inspire and motivate you to ‘hit the ground running’ with a forward-looking approach to launch:
- Understand how best to use data and AI to inform and make decisions.
Pharma organizations will need to navigate an environment of increasing innovation and limited resources as competition continues to intensify and the use of personalized medicine becomes more prevalent. Data and AI are pivotal tools that will enable launch leaders to better optimize, tailor and accelerate the progression of treatments throughout the early commercialization and launch process.
Whether for clinical trial modeling and study optimization or strategic foresight and leveraging insights to refine strategy and plans in real time, launch leaders now need to learn how to use data and AI to prompt better and more efficient decision making. These powerful technologies may increase the likelihood of technical success and support even faster-to-market launch strategies. Technology-supported synthesis of varied data sources will enable rapid trend analysis from launch, the foundational element of any post-launch optimization plan, boosting operational efficiency and subsequently equipping pharma organizations for success.
- Use effective scenario planning to navigate launch uncertainty.
Rapidly advancing technologies, complex regulatory and reimbursement environments, as well as fast-changing market dynamics, have collectively put pharma’s launch environment into a state of continuous evolution. The variability caused by these transitions calls for effective scenario planning when launching a pharma product in 2030.
Too often, scenario planning is deprioritized, but with the innovation of medicines and the healthcare environment, it is key to seize opportunities when they arise and pivot where required. Scenario planning allows an organization to be nimble and adjust to enhance launch optimization. Teams also need to ensure that they leverage strategic foresight in their planning. Rather than developing medicines to beat today’s competitors, it is more about understanding how we can anticipate what our patients will need and how we can differentiate in the market we will be launching into in several years’ time.
- Ensure the right clinical and patient outcomes in trials.
Payers are fragmented and have higher expectations from pharma than ever before, which has largely stemmed from increasingly diverse healthcare systems and rising healthcare costs.
To optimize price and access, it is crucial to understand changes and opportunities in major markets (e.g. Inflation Reduction Act or EU Health Technology Assessment Regulation) and anticipate the diverse needs of payers as well as regulators. By communicating with these stakeholders on a regular basis and at an early stage in the launch process, you will be able to understand their requirements and fine-tune your strategic approach and development plan to meet their priorities.
- Don’t underestimate the power of patient advocacy groups!
Patient advocacy groups (PAGs) influence issues related to rising drug prices, limited access to new therapies, and clinical trial designs. PAGs are responsible for amplifying the patient’s voice, advocating for affordable and accessible therapies, and ensuring that new drugs meet real-world needs.
When we think of patient advocacy groups, the first thing that comes to mind is disease awareness. However, there is much more that can be partnered with patient advocacy groups: policy change and lobbying, patient education on treatment choices, patient insights associated with barriers to treatment, enrollment in clinical trials, and helping to identify meaningful patient outcome measures for patients.
Which aspects do you have well covered through your launch plans and what might you need to devote more attention to? Connect with our Launch Excellence experts on LinkedIn below to keep up to date with the latest advice from the team.
Contact us
